Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2026-07-11), bioAffinity Technologies's 50-Day SMA is $1.48. It's 20-Day SMA is $0.93 and 200-Day SMA is $1.91.
bioAffinity Technologies (NAS:BIAF) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
bioAffinity Technologies 50-Day SMA Related Terms
BIAF vs NDRA, ISPC, ADVB: 50-Day SMA Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies 50-Day SMA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's 50-Day SMA falls into.
bioAffinity Technologies (NAS:BIAF) 50-Day SMA Calculation
The formula for calculating SMA is:
SMA
=
( P1 + P2 + ... + Pn )
/
n
where:
Pn is the price of the stock at period n.
n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a 50-Day SMA of $1.48 as of Jul. 11, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on bioAffinity Technologies and its competitors.
Is bioAffinity Technologies' 50-Day SMA too high?
bioAffinity Technologies' current 50-Day SMA is $1.48. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' 50-Day SMA compare to NDRA and ISPC?
bioAffinity Technologies' 50-Day SMA of $1.48 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Medical Diagnostics & Research company?
A good 50-Day SMA depends on the Medical Diagnostics & Research industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on bioAffinity Technologies and its competitors. bioAffinity Technologies's current 50-Day SMA is $1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current 50-Day SMA is $1.48. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current 50-Day SMA is $1.48 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.26.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
50-Day SMA: $1.48
GF Value™: $4.26 vs. price of $0.76 (82.2% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 